---

Comparative study of control of hyperglycemia and dyslipidemia between two treatment- groups of diabetic patient (Metformin Monotherapy and Metformin + Glimepiride Combination)

Full Text PDF

---

Original Article

Author Details : Subhradipta Bhattacharyya*, Brijesh Mukherjee

Volume : 4, Issue : 3, Year : 2019

Article Page : 91-95

https://doi.org/10.18231/j.ijcaap.2019.019

Suggest article by email

Get Permission

Abstract

Aim: The aim of the study is to examine whether the combination of metformin+ glimepiride is superior to metformin mono therapy to treat the newly diagnosed type 2 DM patients to control the HbA1C and dyslipidaemia in terms of LDL, total cholesterol, TG etc.
Materials and Methods: A Prospective randomised study with four groups. The control comprises of 60 healthy volunteers. 120 newly diagnosed type 2 DM cases (Group 1) were enrolled in the study. These 120 patients were randomised into two groups; Group 2 with 60 patients to receive Metformin and Group 3 with 60 patients to receive Metformin + glimepiride combination. Both the Group 2 and Group 3 have received the same hypolipidemic and antihypertensive drugs.
Results: After about 4 years of treatment, in Group 2 and Group 3, FPG, HbA1C% and lipid profile were improved significantly (p< 0 P=0.85)>
Conclusion: Metformin and Glimepiride combination therapy improves HbA1c, LDL-C, HDL-C more effectively. However, Group 2 patients had shown better AIP than Group 3 patients.

Keywords: Monotherapy, Combination therapy, Glycaemic control, Dyslipidemia, Atherogenesis.

How to cite : Bhattacharyya S, Mukherjee B, Comparative study of control of hyperglycemia and dyslipidemia between two treatment- groups of diabetic patient (Metformin Monotherapy and Metformin + Glimepiride Combination). IP Int J Compr Adv Pharmacol 2019;4(3):91-95

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.